MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. Show more

Dorfstrasse 29, Zug, 6300, Switzerland

https://www.moonlaketx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.491B

52 Wk Range

$5.95 - $62.75

Previous Close

$20.00

Open

$20.33

Volume

1,513,946

Day Range

$19.75 - $20.41

Enterprise Value

1.234B

Cash

357.9M

Avg Qtr Burn

-66.29M

Insider Ownership

8.78%

Institutional Own.

79.72%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Sonelokimab Details Hidradenitis suppurativa	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Hidradenitis suppurativa	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Psoriatic arthritis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Palmoplantar pustulosis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Psoriatic arthritis and Axial spondyloarthritis	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Axial spondyloarthritis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.